Olmutinib: Completed Phase II enrollment

Boehringer completed enrollment of >150 patients who received >=1 line of treatment with an EGFR TKI in the open-label, international Phase II

Read the full 220 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE